EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects

Yaoxiang Lin, Lulu Zheng, Ying Xu, Xinyan Wang, Jie Li iD, Lei Zheng, Guang Liang, Lingfeng Chen iD

Journal of Medicinal Chemistry · 23.01.2025 · 68 (2) · 902-914

DOI: 10.1021/acs.jmedchem.4c01322 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 06.01.2025. Verfasst von Yaoxiang Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Medical College, Hangzhou 310014, China. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Inflammation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 140 Literaturangaben. Gefördert von: Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-1 receptor-associated kinase 4 (IRAK4) is involved in various inflammation-related diseases. Both the kinase and scaffolding functions of IRAK4 initiate pro-inflammatory factor transcription and expression. The scaffolding function of IRAK4 is essential for Myddosome assembly and NF-κB activation. Conventional small-molecule inhibitors effectively inhibit the kinase function of IRAK4 but do not block its scaffolding function. Recently, various IRAK4 degraders have shown promising therapeutic potential in inflammatory diseases. The most advanced IRAK4-selective degrader, KT-474 (SAR444656), significantly reduced inflammatory biomarker levels in patients and demonstrated high safety and tolerability. This perspective introduces and discusses the physiological biology of IRAK4, its associated diseases, and the current development of IRAK4 degraders, thereby offering insights into future research directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Associated KinasesInflammationHumansProtein Kinase InhibitorsAnimalsAnti-Inflammatory Agents

Substanzen

Interleukin-1 Receptor-Associated KinasesIRAK4 protein, humanProtein Kinase InhibitorsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • School of Pharmacy, Hangzhou Medical College, Hangzhou 310014, China.
  • School of Medicine, Hangzhou Normal University, Hangzhou 311121, China.
  • Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou 310000, China.
  • School of Medicine, Zhejiang University City College, Huzhou Road, Hangzhou 310015, China.

ORCID-Profile: Jie Li, Lingfeng Chen

Förderung

  • Key Research and Development Program of Zhejiang Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Health Commission of Zhejiang Province

Zitieren

APA

Lin, Y., Zheng, L., Xu, Y., Wang, X., Li, J., Zheng, L., Liang, G., & Chen, L. (2025). Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects. Journal of Medicinal Chemistry, 68(2), 902-914. https://doi.org/10.1021/acs.jmedchem.4c01322

Vancouver

Lin Y, Zheng L, Xu Y, Wang X, Li J, Zheng L, et al. Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects. Journal of Medicinal Chemistry. 2025;68(2):902-914. doi:10.1021/acs.jmedchem.4c01322

BibTeX
@article{Lin2025,
  author = {Lin, Yaoxiang and Zheng, Lulu and Xu, Ying and Wang, Xinyan and Li, Jie and Zheng, Lei and Liang, Guang and Chen, Lingfeng},
  title = {Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {2},
  pages = {902--914},
  doi = {10.1021/acs.jmedchem.4c01322}
}
Kostenlos starten →